Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 1 · 25%Moderate 1 · 25%High 0 · 0%

Intermittent/cyclic etidronate 400 mg/day vs placebo

Serious adverse events · postmenopausal women with a higher risk for fracturesa

1 finding from 1 review

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Intermittent/cyclic etidronate 400 mg/day vs placebo

Serious adverse events · postmenopausal women at lower risk of fractures1

Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate

Intermittent/cyclic etidronate 400 mg/day vs placebo

Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa

It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
RR 1.09 [0.54, 2.18]
Studies not reported
Very low

Intermittent/cyclic etidronate 400 mg/day vs placebo

Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1

Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
RR 1.41 [0.81, 2.47]
Studies not reported
Low